Australia markets close in 4 hours 2 minutes

INVO Bioscience, Inc. (INVO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0600-0.0300 (-2.75%)
At close: 04:00PM EDT
1.1500 +0.09 (+8.49%)
After hours: 04:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0900
Open1.1200
Bid1.0600 x 3000
Ask1.1500 x 1800
Day's range1.0600 - 1.1600
52-week range1.0600 - 5.4280
Volume81,814
Avg. volume37,479
Market cap12.815M
Beta (5Y monthly)-0.40
PE ratio (TTM)N/A
EPS (TTM)-0.6260
Earnings date15 Aug 2022 - 19 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.50
  • PR Newswire

    INVO Signs Distribution Agreement with Onesky Holding Limited for Mainland China

    INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has entered an exclusive distribution agreement with Onesky Holdings Limited ("Onesky") for Mainland China (excludes Hong Kong, Macau and Taiwan).

  • PR Newswire

    INVO Bioscience Reports First Quarter 2022 Financial Results

    INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

  • PR Newswire

    INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

    INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its first quarter 2022, ended March 31, 2022, after the market close on Monday, May 16, 2022. The Company has scheduled a conference call that same day, Monday, May 16, 2022, at 4:30 pm ET, to review the results.